App-Quantinova.ai

Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study

Allez, M - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Ustekinumab

Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE Open

Allegretti, J.R - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Tasocitinib

Asking teenagers and young adults with IBD; “what matters to you?”. A qualitative survey during the COVID-19 pandemic

King, A - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Indicators for inadequate response to advanced therapy in patients with Ulcerative Colitis: results from a medical chart review in the United Kingdom

Lindsay, J - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Entyvio

Can upskilling pharmacy technicians support a robust and cost-effective Inflammatory Bowel Disease patient review process? A single-centre prospective study.

Rees, F - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Incidence and outcomes of herpes zoster in the ozanimod phase 3 ulcerative colitis and relapsing multiple sclerosis clinical program

Siegmund, B - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Sclerosis

Ozanimod

Faecal infliximab and disease activity in Acute Severe Ulcerative Colitis

Shields, S - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Infliximab

FMT induced increase in gut microbial diversity and Clostridia is associated with clinical response in patients with ulcerative colitis – results from STOP Colitis trial

Quraishi, M.N - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program

Moore, A.C - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Adalimumab biosimilar

Improving food‐related quality of life in Inflammatory Bowel Disease with a novel web-based intervention: a randomised controlled feasibility trial

Cox, S - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome?

Routledge, E - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations

Alice, H - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Entyvio

Exploring phenotype and treatment of inflammatory bowel disease in the elderly

Gaglani, R - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort study

Honap, S - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Tasocitinib

Relationship between haemoglobin status and utility in patients with iron deficiency anaemia in inflammatory bowel disease: A post-hoc analysis of a phase 3 clinical trial

Murphy, D - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Inflammatory bowel disease

Ferric carboxymaltose

The Efficacy and Safety of ustekinumab Therapy in refractory Inflammatory Bowel Disease (IBD) patients with co-morbidities and old age.

Davies, B - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Ustekinumab

Underutilisation of novel and alternative oral iron preparations may incur unnecessary cost in iron deficiency anaemia treatment in inflammatory bowel disease

Sharma, E - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Inflammatory bowel disease

Ferric carboxymaltose

Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn's disease (the SPEED-UP study) - A multi-center study from the paediatric IBD Porto group of ESPGHAN

Yerushalmy-Feler, A - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Crohn's disease

Ustekinumab

Infliximab for induction of medically-induced remission in Crohn's disease: a Cochrane systematic review

Radford, S - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Infliximab

Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naïve and biologic exposed patients

Cheesbrough, J - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Tasocitinib

Filters

45280 Abstracts